Literature DB >> 9795387

A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

M Singh1, J R Carlson, M Briones, M Ugozzoli, J Kazzaz, J Barackman, G Ott, D O'Hagan.   

Abstract

A recombinant form of glycoprotein D from herpes simplex virus type-2 (gD2) was encapsulated into polylactide-co-glycolide (PLG) microparticles using a previously established solvent evaporation technique. The mean size of the microparticles was about 1 micron and high encapsulation efficiency of the antigen was achieved (70-80%). The microparticles were administered intramuscularly to Balb/C mice and the immune responses were compared with those obtained with the oil in water adjuvant MF59. The serum IgG response to gD2 induced by the microparticles was comparable with that induced by MF59. The serum neutralization titres were also comparable for microparticles and the emulsion. However, the microparticles induced a higher IgG2a isotype response and a more potent serum IFN-gamma response than MF59, suggesting a more Th1 type of response. The MF59 induced higher levels of serum IL-4 and IL-5 cytokines, suggesting a more Th2 type of response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795387     DOI: 10.1016/s0264-410x(98)00179-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

Authors:  E J Verschoor; P Mooij; H Oostermeijer; M van der Kolk; P ten Haaft; B Verstrepen; Y Sun; B Morein; L Akerblom; D H Fuller; S W Barnett; J L Heeney
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Calcium phosphate nanoparticle adjuvant.

Authors:  Q He; A R Mitchell; S L Johnson; C Wagner-Bartak; T Morcol; S J Bell
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

3.  Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.

Authors:  William P Halford; Ringo Püschel; Brandon Rakowski
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

4.  Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Authors:  Ashok Cattamanchi; Christine M Posavad; Anna Wald; Yaela Baine; Jennifer Moses; Terry J Higgins; Richard Ginsberg; Richard Ciccarelli; Lawrence Corey; David M Koelle
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

Review 5.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

6.  A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Authors:  Rhea N Coler; Susan L Baldwin; Narek Shaverdian; Sylvie Bertholet; Steven J Reed; Vanitha S Raman; Xiuhua Lu; Joshua DeVos; Kathy Hancock; Jacqueline M Katz; Thomas S Vedvick; Malcolm S Duthie; Christopher H Clegg; Neal Van Hoeven; Steven G Reed
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

Review 7.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

8.  MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.

Authors:  Ming Yang; Youyou Yan; Mingli Fang; Min Wan; Xiuli Wu; Xiaoling Zhang; Tiesuo Zhao; Hongfei Wei; Dandan Song; Liying Wang; Yongli Yu
Journal:  Int Immunopharmacol       Date:  2012-05-14       Impact factor: 4.932

9.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.